How will the field of gene therapy survive its success?
| Autor: | William F. Kaemmerer |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
CITES pay for value gene therapies Biomedical Engineering Pharmaceutical Science Review viral vector manufacturing Field (computer science) 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Order (exchange) non‐viral vectors CAR T‐cell therapies Engineering ethics Business 030217 neurology & neurosurgery Biotechnology |
| Zdroj: | Bioengineering & Translational Medicine |
| ISSN: | 2380-6761 |
| DOI: | 10.1002/btm2.10090 |
| Popis: | In August 2017, for the first time, a gene therapy was approved for market release in the United States. That approval was followed by two others before the end of the year. This article cites primary literature, review articles concerning particular biotechnologies, and press releases by the FDA and others in order to provide an overview of the current status of the field of gene therapy with respect to its translation into practice. Technical hurdles that have been overcome in the past decades are summarized, as are hurdles that need to be the subject of continued research. Then, some social and practical challenges are identified that must be overcome if the field of gene therapy, having survived past failures, is to achieve not only technical and clinical but also market success. One of these, the need for an expanded capacity for the manufacturing of viral vectors to be able to meet the needs of additional gene therapies that will be coming soon, is a challenge that the talents of current and future bioengineers may help address. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |